Details of the Drug

General Information of Drug (ID: DMKFRWU)

• Drug Name: Anetumab ravtansine
• Synonyms: Mesothelin-ADC

Indication

Disease Entry	ICD 11	Status	REF
Malignant pleural mesothelioma	2C26.0	Phase 2	[1]
Mesothelioma	2C51.2	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Ovarian cancer	2C73	Phase 1	[1]

• Drug Type: Antibody drug conjugate
• Cross-matching ID:
  UNII: M170940PMI
  DrugBank ID: DB14809
  TTD ID: D0CN9D
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT03926143) A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies. U.S. National Institutes of Health.